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The Global Polio Eradication Initiative, launched in 1988, is close to achieving its goal. In 2015, reported cases of
wild poliovirus were limited to just two countries – Afghanistan and Pakistan. Africa has been polio-free for more
than 18 months. Remaining barriers to global eradication include insecurity in areas such as Northwest Pakistan and
Eastern and Southern Afghanistan, where polio cases continue to be reported. Hostility to vaccination is either
based on extreme ideologies, such as in Pakistan, vaccination fatigue by parents whose children have received
more than 15 doses, and misunderstandings about the vaccine’s safety and effectiveness such as in Ukraine. A
further challenge is continued circulation of vaccine-derived poliovirus in populations with low immunity, with 28
cases reported in 2015 in countries as diverse as Madagascar, Ukraine, Laos, and Myanmar. This paper summarizes
the current epidemiology of wild and vaccine-derived poliovirus, and describes the remaining challenges to
eradication and innovative approaches being taken to overcome them.
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Background
We may be witnessing the last stand of the wild
poliovirus (WPV). In 2015, approximately 70 cases of
WPV were reported in only two countries – Pakistan
and Afghanistan, representing approximately 0.02 % of
the global polio burden in 1988, the year the Global
Polio Eradication Initiative (GPEI) was launched [1]. As
of the end of February, only five cases had been reported
in 2016, and all in Pakistan [2]. Polio is not a ‘tropical
disease’ and therefore represented a major problem in
many developed countries until the 1960s. For example,
in 1952, there were 58,000 cases of paralytic polio in the
United States, resulting in 3,145 deaths and 22,000
people left with varying degrees of paralysis [3].
WPV is transmitted via the fecal-oral route and, there-
fore, thrives in environments where sanitation is poor.
There are three types of WPV – 1, 2, and 3 – all of
which can cause severe paralysis or death. However,
for every 200 people infected (mostly children), only
one develops paralysis, 20 have non-specific symp-
toms, and 180 are asymptomatic [4]. This creates
challenges for surveillance as the virus may circulate
undetected. There has been no case of WPV2 since
October 1999 and it was officially declared eradicated
in September 2015; WPV3 has not been detected
since November 2012.
The most common polio vaccine used worldwide is
the trivalent oral polio vaccine (OPV), which contains
three types of live, attenuated (weakened) vaccine-
viruses. OPV induces immunity against all three types of
WPV in the gut of a vaccinated child, thus preventing
the viruses from entering the bloodstream and the ner-
vous system to cause paralysis. In most countries, three
or four vaccine doses are adequate to protect a child
from infection. However, in areas where water quality,
sanitation, and hygiene are poor, children may require
ten or more doses because the many other viruses and
bacteria that infect their gut interfere with the body’s
ability to mount an effective immune response, as
was the case in the last reservoirs of polio in India –
impoverished and densely populated districts of Bihar
and Uttar Pradesh States [5]. Therefore, vaccines that
target just one (‘monovalent’) or two (‘bivalent’) of
the virus strains and induce higher levels of immunity
than the trivalent vaccine were developed [6].
Vaccine-associated paralytic poliomyelitis occurs in an
estimated 1 in 2.7 million children receiving their first
OPV dose, which is why most upper-income countriesCorrespondence: toole@burnet.edu.au
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have switched to the injectable, inactivated (dead) polio
vaccine, which induces immunity in the bloodstream.
Additionally, after a child is vaccinated, some of the
vaccine-virus may be genetically altered during replica-
tion upon excretion, and is subsequently termed a
vaccine-derived poliovirus. On rare occasions, there are
enough susceptible children for the excreted viruses to
begin circulating and cause paralytic cases in popula-
tions with low immunity; these viruses are called circu-
lating vaccine-derived polioviruses (cVDPV) [7].
Global Polio Eradication Initiative (GPEI)
The GPEI was launched in 1988, when approximately
350,000 children were paralyzed by polio every year [8].
Initial progress was rapid; the last case of WPV in the
WHO region of the Americas occurred in 1993 and the
last case in the Western Pacific region (which includes
China) occurred in 1997 [9]. However, the initial target
of the GPEI to eradicate polio from the world by the
year 2000 was not achieved [10]. Progress was slow for
the subsequent decade; the number of cases reported in
2010 was higher than in 2000 and 20 countries were still
reporting polio.
Since 2010, although deadlines for interrupting WPV
transmission were missed in 2012 and 2015, significant
progress has been made, including elimination in India
and Nigeria. Globally, WPV cases declined from 1,352
in 2010 to 74 in just two countries in 2015 (WHO
data 2 March 2016) [11]. The African continent has
been WPV-free since August 2014.
Figure 1 shows the number of reported cases of WPV
in Afghanistan, Pakistan, Nigeria, and non-endemic
countries between 2011 and 2015 (data from [2]).
The GPEI is led by five partners that comprise the
Polio Oversight Board, namely the World Health
Organization, UNICEF, Rotary International, the US
Centers for Disease Control and Prevention, and the
Bill & Melinda Gates Foundation. The Independent
Monitoring Board (IMB) was convened in late 2010
at the request of the World Health Assembly to
monitor and guide progress towards eradication.
We are on the cusp of a polio-free world; however,
several challenges need to be overcome in order to
meet the deadline set by the Polio Oversight Board to
interrupt WPV transmission in 2016. This commen-
tary will discuss these major barriers, and briefly illus-




Since 2010, armed conflict and insecurity have been
major constraints to accessing children for polio vaccin-
ation in the endemic countries of Afghanistan, Pakistan
and Nigeria, and countries that experienced outbreaks
such as Somalia, Cote d’Ivoire, Syria, Democratic Republic
of Congo, Mali, and Iraq.
Nevertheless, innovative communication and access
strategies, such as employing local respected intermedi-
aries to negotiate with anti-government elements, have
overcome the barrier of insecurity in most countries. In
Northeast Nigeria, where the militant Boko Haram
group disrupted vaccination campaigns, temporary ‘health
camps’ were established offering a range of health services
in addition to the polio vaccine [12]. Visiting Afghanistan
on behalf of the IMB, I witnessed several innovative efforts
Fig. 1 The annual number of wild poliovirus cases reported in Pakistan, Afghanistan, Nigeria and non-endemic countries, 2011-2015. Source:
World Health Organization. Global Polio Eradication Initiative. Data and Monitoring. http://www.polioeradication.org/Dataandmonitoring.aspx
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to overcome security barriers. In Kandahar province, per-
manent polio vaccination teams were established to take
advantage of all opportunities to vaccinate children such
as market days. In Jalalabad, ‘women’s courtyards’ provided
safe spaces for women to discuss the benefits of
vaccination.
Hostility to vaccination
The refusal by parents to vaccinate their children is due
to a number of factors, ranging from ‘vaccination
fatigue’, in countries where children may have been vac-
cinated 15 or more times, to outright bans by militant
groups such as Al Shabaab in Somalia [13]. The situ-
ation is most toxic in Pakistan, where the Taliban has
banned polio vaccination in North and South Waziristan
and incited violence against vaccinators and their police
escorts [14]. As recently as January 13, 2016, a suicide
bomber detonated explosives outside a polio vaccination
center in the city of Quetta, killing 15 and wounding
24 people [15].
A number of initiatives have been launched to coun-
ter misinformation about polio vaccine in the guise of
religious doctrine. A meeting of Islamic scholars con-
vened at Cairo’s renowned Al-Azhar University in
March 2014, and led to the formation of an Islamic
Advisory Group for Polio Eradication [16]. Fatwas sup-
porting polio vaccination by the Grand Imam of Al
Azhar and other leading Islamic clerics have since
been widely disseminated and tens of thousands of
social mobilizers have been trained to disseminate in-
formation on vaccination by word-of-mouth. During a
visit to Chad on behalf of the IMB, I visited a com-
munity where the spiritual leader, Sheikh Ousman,
preached that it was every parent’s duty to vaccinate
their children against polio and other preventable dis-
eases. As a result, according to local Chadian officials
(unpublished data), a 100 % coverage in vaccination
campaigns was achieved.
Vaccine-derived polio
As described earlier, vaccine-derived poliovirus may
sometimes circulate, causing paralytic cases in popula-
tions with low immunity. Prior to 2015, most cases of
cVDPV had been Type 2. Since there has been no case
of WPV Type 2 since 1999, WHO’s Strategic Advisory
Group of Experts on Immunization (SAGE) concluded,
in October 2015, that the switch from trivalent to
bivalent OPV (Types 1 and 3) should go ahead globally
in April 2016 [17]. There was a resurgence of Type 1
cVDPV in 2015, with 17 cases reported in Laos,
Madagascar, and Ukraine, reflecting diminished levels of
immunity in these populations; for example, in mid-
2015, only half of Ukrainian children had been fully
vaccinated against polio [18].
The way forward
The title of the IMB’s most recent report was “Now is
the Time for Peak Performance” [19]. Indeed, the
current low season of transmission (through May 2016)
is the time to implement high-quality campaigns that
achieve the greatest possible vaccination coverage, espe-
cially in areas such as southern Afghanistan, where large
proportions of children are missed during campaigns.
The combined use of OPV and inactivated polio vac-
cine in campaigns is likely to boost population immunity
and should be employed routinely in endemic countries
and others that are vulnerable to reintroduction of WPV
(e.g. Nigeria, Cameroon, Chad, Somalia, and Yemen).
Environmental surveillance should be rapidly ex-
panded throughout Pakistan and Afghanistan coupled
with rigorous outbreak response action when positive
samples are found. Since WPV causes paralysis in less
than 1 % of infected children, an ‘orphan’ virus may
circulate undetected by routine acute flaccid paralysis
surveillance [20]. In addition, surveillance ‘blackspots’
need to be addressed in countries where international
surveillance indicators are not met.
High-level political commitment is essential at the
national level to ensure accountability for campaign
quality by provincial governors in Afghanistan and
state governments in Pakistan and Nigeria. However,
at the frontline, the polio campaign needs to be polit-
ically neutral to avoid negative responses from anti-
government elements.
The rest of the world cannot be complacent. Reintro-
duction of WPV led to a major outbreak in Somalia in
2013 after a ban by armed militants led to half a million
children going unimmunized for three years. Recent
clusters of vaccine-derived poliovirus in countries as
diverse as Ukraine, Myanmar, and Madagascar indicate
low population immunity.
Conclusions
If we are to succeed in eradicating the second human
disease in history during 2016, an unprecedented global
endeavor will be required, involving parents, vaccinators,
community and religious leaders, state, province and
national governments, political leaders, international
technical agencies, and the world’s major aid donors.
While eradication of this terrible disease is clearly for
the global public good, we cannot presume that support
will be universal. Radical political forces in a number of
countries have demonstrated that they will put their
own agenda ahead of the well-being of children. Innova-
tive (and politically-neutral) actions are needed to over-
come the barriers of insecurity and hostility.
The GPEI provides important lessons for future dis-
ease eradication efforts. First, disease eradication is not
easy and requires sustained financial and technical
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support. Second, it will not succeed without high-
level political commitment, intense coordination, and
mobilization of communities and their leaders. Third,
global campaigns can benefit from oversight by an in-
dependent review body such as the Polio IMB. This
time next year, let us hope that the fourth lesson will
be that it can be done.
Competing interests
MT has been a member of the Independent Monitoring Board of the Global
Polio Eradication Initiative since 2010. During this time, he has made field
visits funded by the World Health Organization to Afghanistan and Chad.
Received: 2 March 2016 Accepted: 2 March 2016
References
1. US Centers for Disease Control and Prevention. Infographic: The Time to
Eradicate Polio is Now. http://www.cdc.gov/globalhealth/immunization/
infographic/eradicate_polio.htm. Accessed 16 January 2016.
2. World Health Organization. Global Polio Eradication Initiative. Data and
Monitoring. http://www.polioeradication.org/Dataandmonitoring.aspx.
Accessed 29 February 2016.
3. Smith JS. Patenting the Sun: Polio and the Salk Vaccine. New York, NY:
William Morrow and Company, Inc; 1990. p. 157.
4. US Centers for Disease Control and Prevention. Global Health – Polio.
http://www.cdc.gov/polio/about/. Accessed 27 February 2016.
5. United Nations Children’s Fund (UNICEF). A critical leap to polio eradication
in India. 2003. p. 13. http://www.unicef.org/rosa/critical.pdf. Accessed
March 8, 2016.
6. Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H, et al.
Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a
randomised, double-blind, controlled trial. Lancet. 2010;376:1682–8.
7. Kew OM, Wright PF, Agol VI, Delpeyroux F, Shimizu H, Nathanson N, et al.
Circulating vaccine-derived polioviruses: current state of knowledge.
Bull World Health Organ. 2004;82(1):16–23.
8. Polio: eradication. Nature Web Focus. http://www.nature.com/nature/focus/
polio/eradication.html. Accessed March 8, 2016.
9. World Health Organization. Global Polio Eradication Initiative. History of
polio. http://www.polioeradication.org/Polioandprevention/Historyofpolio.
aspx. Accessed 28 February 2016.
10. Independent Monitoring Board of the Global Polio Eradication Initiative.
Report, April 2011. http://www.polioeradication.org/Portals/0/Document/
Data&Monitoring/IMB_Reports/IMB_Report_April2011.pdf.
11. World Health Organization. Global Polio Eradication Initiative. Weekly Polio
Update. http://www.polioeradication.org/dataandmonitoring/poliothisweek.
aspx. Accessed 8 March 2016.
12. Patil N. Health Camps: Expanding Access to Healthcare during Polio
Immunization Campaigns in Northern Nigeria. OpenIDEO Report. 2014.
https://challenges.openideo.com/challenge/zero-to-five/research/health-
camps-expanding-access-to-healthcare-during-polio-immunization-
campaigns-in-northern-nigeria. Accessed 12 January 2016.
13. IRIN News. Thousands at Risk of Polio in Somalia’s Port City of Kismayo.
2012. http://www.irinnews.org/report/96744/in-brief-thousands-at-risk-of-
polio-in-somalia-s-port-city-of-kismayo. Accessed 12 January 2016.




15. Boone J. Bomb attack at polio vaccination centre kills 15 in Pakistani city of
Quetta. The Guardian. 2016. http://www.theguardian.com/world/2016/jan/
13/bomb-attack-at-polio-vaccination-centre-kills-14-in-pakistani-city-of-
quetta. Accessed 14 January 2016.
16. Islamic Advisory Group for Polio Eradication. http://www.iag-group.org/iag/
home/. Accessed 18 January 2016.
17. World Health Organization. Introduction of inactivated polio vaccine and
switch from trivalent to bivalent oral poliovirus vaccine worldwide,
2013–2016. Wkly Epidemiol Rec. 2015;90(27):337–42.
18. World Health Organization. Emergencies, preparedness, response.
Circulating vaccine-derived poliovirus – Ukraine. September 1, 2015.
http://www.who.int/csr/don/01-september-2015-polio/en/. Accessed
1 March 2016.
19. Independent Monitoring Board of the Global Polio Eradication Initiative.
Now is the Time for Peak Performance. Twelfth Report: October 2015.
http://www.polioeradication.org/Portals/0/Document/Aboutus/Governance/
IMB/13IMBMeeting/13IMB_Report_EN.pdf.
20. Asghar H, Diop OM, Weldegebriel G, Malik F, Shetty S, El Bassioni L, et al.
Environmental surveillance for polioviruses in the Global Polio Eradication
Initiative. J Infect Dis. 2014;210 Suppl 1:S294–303.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Toole BMC Medicine  (2016) 14:43 Page 4 of 4
